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Abstract
Background: In 2007, we reported a summary of data comparing diabetic foot complications to cancer. The
purpose of this brief report was to refresh this with the best available data as they currently exist. Since that time,
more reports have emerged both on cancer mortality and mortality associated with diabetic foot ulcer (DFU),
Charcot arthropathy, and diabetes-associated lower extremity amputation.
Methods: We collected data reporting 5-year mortality from studies published following 2007 and calculated a
pooled mean. We evaluated data from DFU, Charcot arthropathy and lower extremity amputation. We dichotomized
high and low amputation as proximal and distal to the ankle, respectively. This was compared with cancer mortality as
reported by the American Cancer Society and the National Cancer Institute.
Results: Five year mortality for Charcot, DFU, minor and major amputations were 29.0, 30.5, 46.2 and 56.6%,
respectively. This is compared to 9.0% for breast cancer and 80.0% for lung cancer. 5 year pooled mortality for all
reported cancer was 31.0%.
Direct costs of care for diabetes in general was $237 billion in 2017. This is compared to $80 billion for cancer in 2015.
As up to one-third of the direct costs of care for diabetes may be attributed to the lower extremity, these are also
readily comparable.
Conclusion: Diabetic lower extremity complications remain enormously burdensome. Most notably, DFU and LEA
appear to be more than just a marker of poor health. They are independent risk factors associated with premature
death. While advances continue to improve outcomes of care for people with DFU and amputation, efforts should be
directed at primary prevention as well as those for patients in diabetic foot ulcer remission to maximize ulcer-free,
hospital-free and activity-rich days.
Up to one-third of the half billion people with diabetes
worldwide will develop a diabetic foot ulcer (DFU) over
the course of their lifetime. Over half of DFUs will
develop an infection. Of these, 17% will require an am-
putation [1–4]. Remarkably, people with diabetes fear
amputation worse than death [5]. For patients who do
not receive amputation and are able to heal their ulcer,
40% will develop a recurrence within 1 year, 65% within
5 years, and greater than 90% within 10 years [1, 6]. The
greatest risk factor for a DFU is a previously healed
DFU. These silent, sinister complications are now a lead-
ing cause of disability worldwide [7, 8]. Despite this high
prevalence and morbidity, federal funding for studies re-
lated to DFUs remains at a 600-plus-fold disadvantage
compared to other diabetes research in terms of public
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health impact. The disparity is even greater when com-
pared to cancer research [9].
In 2007, we reported a summary of data comparing
diabetic foot complications to cancer [10]. We thought
that it might be appropriate to refresh this with the best
available data as they currently exist. Since that time,
more reports have emerged both on cancer mortality
[11] and mortality associated with DFU, [12–14] Charcot
arthropathy, [15–17] and diabetes-associated lower ex-
tremity amputation [18–27]. We collected data containing
5-year mortality from studies published after the previous
publication in 2007 and calculated a pooled mean.
The mortality rate for people who undergo lower extremity
amputation due to a DFU remains alarming: more than half
of people with a major amputation will be dead in 5 years
[21–25]. (Fig. 1). 5 year mortality for Charcot, DFU, minor
and major amputations were 29.0, 30.5, 46.2 and 56.6%, re-
spectively. This is even higher in people with concomitant
chronic kidney disease and other comorbidities [25].
Certainly, an important component of mortality in
people with lower extremity complications of diabetes
can be attributed to the severity of comorbidities with
these patients often present - namely cardiovascular and
renal disease worsened by reduced mobility [7]. This
most certainly further reduces the attribution of cause
away from lower extremity morbidity and toward a more
familiar cardiovascular etiology. Indeed, people with a
history of DFU have a life expectancy fully 5 years lower
than age and disease-matched controls. The primary
cause of death in these patients was listed as ischemic
heart disease [30]. It is important to note, however, that,
DFU and LEA appear to be more than just a marker of
poor health. They are independent risk factors associ-
ated with premature death [31].
It is for these reasons that we have argued for a change
in the syntax surrounding DFUs and other associated
complications. Considering patients with healed DFUs as
patients “in remission” rather than formally “healed”
makes it easier for the patient, other clinicians, and pol-
icymakers to understand the possibility, or as the data
suggest, probability, of a recurrence and to better com-
municate overall risk [1, 32]. It also indicates the need
for regular follow-up and helps to prepare the patient
for a lifetime of preventative management and mobility
training [32]. With this mindset, patients can be properly
educated about the dangers of diabetic foot disease and
work towards maximizing ulcer-free, hospital-free, and
activity-rich days, the same way a cancer survivor works
to maximize cancer-free days [33, 34].
The economic cost of DFUs
DFUs place a great economic burden on society, both to
our healthcare system and due to lost productivity. In
2017, diabetes directly cost $237 billion in the USA, a
26% increase from 2012. On the order of one-third of
these direct costs were attributable to care for diabetic
foot disease [1, 35, 36]. In remarkable contrast, the 2015
direct costs for cancer in the USA were $80.2 billion -
nearly equal to the attributable cost of diabetic foot
disease [37]. As the number of people with diabetes is
expected to rise over the coming decades we do not
expect this cost or the rate at which it spirals out of
Fig. 1 Five Year Mortality of Diabetic Foot Complications and Cancer. Diabetic foot complications compared to cancer. DFU = diabetic foot ulcers
[11] = 30.5%. Charcot = Charcot neuroarthropathy of the foot [14]. All Cancer = pooled 5 year survival of all cancers [11]. CLTI = chronic limb
threatening ischemia [28, 29]. Major Amputation = above foot amputation [20–22, 26, 27]. Minor Amputation = foot level amputation [17, 27]
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control to slow down unless more serious measures are
spent on preventive education and care. The U.S.
National Cancer Institute’s budget is currently $6.4
billion to explore technological innovations in treat-
ments and cures for cancer, and there should be a pro-
portional response for diabetic foot disease [38].
Although patient education can play an important first
step in the management of diabetic foot disease, new
technologies are emerging which may help to reduce
healing times, ulcer severity at clinical presentation, and
overall costs.
Additionally, the emergence of remote patient moni-
toring technologies can allow us to predict and detect
ulcers as or even before they form. Patients using a
smart insole system, pressure-monitoring insoles trans-
mitting real-time feedback to a smartwatch to cue off-
loading of sustained plantar pressure, in addition to the
regular standard-of-care have been shown to have sub-
stantially lower rates of ulcer occurrence and approxi-
mately $15,000 less cost of care when ulcers do form,
over a period of 18 months [39, 40]. In another study, a
smart temperature-monitoring bathmat was able to de-
tect DFUs 5 weeks before clinical presentation [41]. Fur-
ther, in-clinic hyperspectral imaging devices have shown
great promise in detecting wound formation weeks in
advance and providing clinicians with useful information
into the blood flow to current wounds, aiding in treat-
ment decision-making [42]. Since the difference in cost
between an early-stage DFU and a more severe DFU is
at least an order of magnitude lower in almost every
economy measured, [43] technologies that can help
identify DFUs early or before they even form will be use-
ful tools for patients, clinicians and health systems [44].
As these devices progress to be used in the home, along
with other easy-to-use devices, we are hopeful that these
technologies will help to alleviate the incidence of and
costs associated with DFUs.
Altogether, these breakthroughs in technology and
best-practice adherence offer providers and patients with
economically dominant strategies to manage diabetic
foot complications. Such strives are critical since the an-
ticipated $80 billion currently being spent on diabetic
foot disease is not sustainable. For merely pennies on
the dollar, investment in prevention of this concerning
complication represents a more economical practice and
is better for the patient. Furthermore, monetary savings
gained from the transition between treatment and pre-
vention can be used to perpetuate further investments to
address mitigating root causes of diabetes complications
so that future patients suffer less.
In summary, complications associated with diabetic foot
disease remain common, complex and costly. The eco-
nomic impact of diabetic foot disease is comparable to
cancer in every single way, but supportive technologies to
predict and prevent onset offers healthcare potential sav-
ings in the short-run. Most importantly, focusing on
early-stage preventative therapies and long-term support-
ive therapies for people in diabetic foot remission may
yield both a greater lifespan and healthspan for the people
we serve.
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